Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2019 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Enterococcus faecium Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 17 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Key Topics Covered:

• Introduction
• Report Coverage
• Vancomycin-Resistant Enterococcus faecium Infections – Overview
• Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics Development
• Pipeline Overview
• Pipeline by Companies
• Pipeline by Universities/Institutes
• Products under Development by Companies
• Products under Development by Universities/Institutes
• Vancomycin-Resistant Enterococcus faecium Infections – Therapeutics Assessment
• Assessment by Target
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• Vancomycin-Resistant Enterococcus faecium Infections – Companies Involved in Therapeutics Development
• Acurx Pharmaceuticals LLC
• AimMax Therapeutics Inc
• Alchemia Ltd
• AnyGen Co Ltd
• Aphios Corp
• Arietis Corp
• Armata Pharmaceuticals Inc
• AzurRx BioPharma Inc
• Curza Global LLC
• Daiichi Sankyo Co Ltd
• Ferring International Center SA
• Helix BioMedix Inc
• Hsiri Therapeutics LLC
• Karveel Pharmaceuticals
• MGB Biopharma Ltd
• MicuRx Pharmaceuticals Inc
• Naicons Srl
• NovoBiotic Pharmaceuticals LLC
• Opal Biosciences Ltd
• Oragenics Inc
• Ovensa Inc
• Sealife PHARMA GMBH
• Sentinella Pharmaceuticals Inc
• Wockhardt Ltd
• Vancomycin-Resistant Enterococcus faecium Infections – Drug Profiles
• ACX-375C – Drug Profile
• AGM-290 – Drug Profile
• APY-281 – Drug Profile
• AZX-1103 – Drug Profile
• BDM-I – Drug Profile
• contezolid – Drug Profile
• HB-1345 – Drug Profile
• HT-01 – Drug Profile
• HT-02 – Drug Profile
• IBN-1 – Drug Profile
• Marinus – Drug Profile
• MGBBP-3 – Drug Profile
• NAI-107 – Drug Profile
• NAI-108 – Drug Profile
• NAI-603 – Drug Profile
• Novo-29 – Drug Profile
• OG-253 – Drug Profile
• RBX-2660 – Drug Profile
• SLP-0901 – Drug Profile
• SLP-0904 – Drug Profile
• SLP-0905 – Drug Profile
• Small Molecule for Gram-Positive Bacterial Infections – Drug Profile
• Small Molecule for Methicillin-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococcus Infections – Drug Profile
• Small Molecules for Bacterial Infections – Drug Profile
• Small Molecules for Bacterial Infections – Drug Profile
• Small Molecules for Gram-Positive Bacterial Infections – Drug Profile
• Small Molecules for Infectious Diseases – Drug Profile
• Small Molecules to Activate CLPP for Vancomycin Resistant Enterococci Infections – Drug Profile
• Small Molecules to Inhibit ftsz for Infectious Disease – Drug Profile
• Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections – Drug Profile
• Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections – Drug Profile
• SNP-021062 – Drug Profile
• Synthetic Peptides for Vancomycin Resistant Enterococci Infections – Drug Profile
• WCK-4086 – Drug Profile
• Vancomycin-Resistant Enterococcus faecium Infections – Dormant Projects
• Vancomycin-Resistant Enterococcus faecium Infections – Discontinued Products
• Vancomycin-Resistant Enterococcus faecium Infections – Product Development Milestones
• Featured News & Press Releases

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nxh6j8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900